Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Tallac’s pipeline of immunotherapy candidates are derived from the company’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration. Several TRAAC molecules are in various stages of discovery and preclinical development. 

Biotechnology

Health Care

Therapeutics

Tallac Therapeutics

Tallac Therapeutics' headquarters in Burlingame, CA, United States

Curtis Hecht

Mark Karbarz

Ons H.

Maja Zukic Bonacorsi

Emma S.

The Science and Research team at Tallac Therapeutics is dedicated to driving the discovery and preclinical development of novel immunotherapy candidates using the TRAAC platform. This team, comprising experts in clinical sciences, preclinical development, biologics discovery, and translational research, collaborates to advance the company's pipeline of TLR9 agonist-based therapies. They focus on rigorous scientific research, biomarker development, and translational strategies to ensure potent and targeted immune activation against cancer.

Science and Research

The Leadership Team at Tallac Therapeutics spearheads the strategic direction and operational management of the company. Comprising top executives, including the President, Chief Executive Officer, and various Vice Presidents overseeing clinical sciences, preclinical development, business operations, research, and biologics discovery, this team drives the advancement of the company's immunotherapy pipeline. They ensure the alignment of scientific innovation with business goals, regulatory compliance, and overall organizational growth.

Tallac Therapeutics

Org chart

Teams

Science and Research

Leadership Team

Offices

Tallac Therapeutics

Org chart

Teams

Science and Research

Leadership Team

Offices

Related companies